Inflammatory bowel diseases (IBD) manifest not only in the gastrointestinal (GI) tract, but also affect joints, skin, eyes, liver, lung, and pancreas. Up to half of patients with IBD have extraintestinal manifestations (EIMs) of IBD. Therapies for intestinal inflammation are not sufficient to treat EIMs such as anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangitis (PSC), which usually occur independent of disease flares. In the October issue of Gastroenterology, Gerhard Rogler et al review the epidemiology, pathophysiology, clinical presentation, and treatment of EIMs in patients with IBD.
Trending
- A Focus on Quality Colonoscopy Bowel Preparation (GI & Endoscopy News)
- Innovating IBD Treatment Using Behavioral Health Tactics (AJMC)
- Fecal transplants: Promising treatment or potential health risk? (Medical Xpress)
- Dr Micheal Tadros on GLP-1 Agonists in Gastroenterology (Gastroenterology Learning Network)
- Why AI Can (and Will) Be a Valuable Tool in the Clinician’s Toolbox (HealthLeaders)
- Great Neck Gastroenterologist Charged with More Than $100,000 Social Security Benefits Fraud (District Attorney)
- Guardant Health Wins Fast Company’s 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening (Business Wire)
- Medicare Physician Gastrointestinal Procedure Pay Fell; Facility Pay Rose (Medscape)